Breaking News

Cingulate, Camargo Enter Regulatory Consulting Agreement

To provide regulatory consulting and strategic development services for two ADHD drugs

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cingulate Therapeutics, LLC, a clinical stage biopharma company, has entered into service agreements with Camargo Pharmaceutical Services, LLC for regulatory consulting and strategic development services. This includes pre-Investigational New Drug (pre-IND) meeting planning and preparations through New Drug Applications (NDA) submissions, for Cingulate’s two, first-line stimulant medications for the treatment of Attention Deficit – Hyperactivity Disorder (ADHD), CTX-1301 and CTX-1302. Cing...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters